The Rise of Fentanyl: Molecular Aspects and Forensic Investigations.

Cecilia Barletta, Virginia Di Natale, Massimiliano Esposito, Mario Chisari, Giuseppe Cocimano, Lucio Di Mauro, Monica Salerno, Francesco Sessa
Author Information
  1. Cecilia Barletta: Legal Medicine, Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.
  2. Virginia Di Natale: Legal Medicine, Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.
  3. Massimiliano Esposito: Faculty of Medicine and Surgery, "Kore" University of Enna, 94100 Enna, Italy. ORCID
  4. Mario Chisari: "Rodolico-San Marco" Hospital, Santa Sofia Street, 87, 95121 Catania, Italy.
  5. Giuseppe Cocimano: Department of Mental and Physical Health and Preventive Medicine, University of Campania "Vanvitelli", 80121 Napoli, Italy.
  6. Lucio Di Mauro: Legal Medicine, Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.
  7. Monica Salerno: Legal Medicine, Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy.
  8. Francesco Sessa: Legal Medicine, Department of Medical, Surgical and Advanced Technologies "G.F. Ingrassia", University of Catania, 95123 Catania, Italy. ORCID

Abstract

Fentanyl is a synthetic opioid widely used for its potent analgesic effects in chronic pain management and intraoperative anesthesia. However, its high potency, low cost, and accessibility have also made it a significant drug of abuse, contributing to the global opioid epidemic. This review aims to provide an in-depth analysis of fentanyl's medical applications, pharmacokinetics, metabolism, and pharmacogenetics while examining its adverse effects and forensic implications. Special attention is given to its misuse, polydrug interactions, and the challenges in determining the cause of death in fentanyl-related fatalities. Fentanyl misuse has escalated dramatically, driven by its substitution for heroin and its availability through online platforms, including the dark web. Polydrug use, where fentanyl is combined with substances like xylazine, alcohol, benzodiazepines, or cocaine, exacerbates its toxicity and increases the risk of fatal outcomes. Fentanyl undergoes rapid distribution, metabolism by into inactive metabolites, and renal excretion. Genetic polymorphisms in , , and significantly influence individual responses to fentanyl, affecting its efficacy and potential for toxicity. Fentanyl's side effects include respiratory depression, cardiac arrhythmias, gastrointestinal dysfunction, and neurocognitive impairments. Chronic misuse disrupts brain function, contributes to mental health disorders, and poses risks for younger and older populations alike. Fentanyl-related deaths require comprehensive forensic investigations, including judicial inspections, autopsies, and toxicological analyses. Additionally, the co-administration of xylazine presents distinct challenges for the scientific community. Histological and immunohistochemical studies are essential for understanding organ-specific damage, while pharmacogenetic testing can identify individual susceptibilities. The growing prevalence of fentanyl abuse highlights the need for robust forensic protocols, advanced research into its pharmacogenetic variability, and strategies to mitigate its misuse. International collaboration, public education, and harm reduction measures are critical for addressing the fentanyl crisis effectively.

Keywords

References

  1. J Anal Toxicol. 2006 Mar;30(2):65-72 [PMID: 16620540]
  2. Neuropsychopharmacology. 2018 Mar;43(4):810-819 [PMID: 28849778]
  3. Curr Pain Headache Rep. 2024 May;28(5):417-426 [PMID: 38507135]
  4. Toxicol Lett. 2016 Sep 6;258:29-35 [PMID: 27265246]
  5. J Anal Toxicol. 2017 Apr 1;41(3):242-249 [PMID: 28096302]
  6. Pharmgenomics Pers Med. 2024 Jan 30;17:41-49 [PMID: 38313794]
  7. Pharmacogenomics. 2017 Apr;18(5):417-419 [PMID: 28346084]
  8. Health Justice. 2021 Nov 24;9(1):34 [PMID: 34817717]
  9. Int J Drug Policy. 2024 Mar;125:104338 [PMID: 38364357]
  10. Br J Clin Pharmacol. 2017 Feb;83(2):294-313 [PMID: 27619152]
  11. Pharmacogenet Genomics. 2020 Jan;30(1):5-8 [PMID: 31651722]
  12. Brain Res Bull. 2024 Apr;209:110917 [PMID: 38428507]
  13. BMJ. 2010 Aug 31;341:c4462 [PMID: 20807731]
  14. Methods Find Exp Clin Pharmacol. 2003 Jan-Feb;25(1):5-10 [PMID: 12690700]
  15. JAMA. 2023 Jun 13;329(22):1904-1906 [PMID: 37223922]
  16. Forensic Sci Res. 2017 Jan 16;1(1):42-51 [PMID: 30483610]
  17. Front Psychiatry. 2024 Jan 10;14:1332999 [PMID: 38268564]
  18. Neuropsychopharmacology. 2017 Jan;42(1):156-177 [PMID: 27402494]
  19. PLoS One. 2018 May 24;13(5):e0197734 [PMID: 29795628]
  20. JHEP Rep. 2019 Jul 09;1(3):240-255 [PMID: 32039374]
  21. World Psychiatry. 2023 Jun;22(2):203-229 [PMID: 37159360]
  22. Diagnostics (Basel). 2024 Sep 09;14(17): [PMID: 39272779]
  23. Neurobiol Stress. 2024 Mar 18;30:100629 [PMID: 38584880]
  24. Pain. 2013 Nov;154(11):2287-2296 [PMID: 23792283]
  25. Toxics. 2024 Sep 24;12(10): [PMID: 39453110]
  26. Anaesthesia. 2008 Oct;63(10):1056-60 [PMID: 18616522]
  27. Int J Hepatol. 2012;2012:158547 [PMID: 22973518]
  28. Indian J Crit Care Med. 2014 Jul;18(7):421-6 [PMID: 25097353]
  29. Curr Neuropharmacol. 2017 Nov 14;15(8):1156-1173 [PMID: 28474563]
  30. Br J Anaesth. 2019 Jun;122(6):e136-e145 [PMID: 31010646]
  31. J Clin Endocrinol Metab. 2020 Mar 1;105(3): [PMID: 31511863]
  32. JAMA Netw Open. 2020 Apr 1;3(4):e202361 [PMID: 32271389]
  33. Front Neurosci. 2023 Apr 06;17:1134842 [PMID: 37090798]
  34. Drug Alcohol Depend Rep. 2023 Mar 29;7:100150 [PMID: 37069960]
  35. Toxics. 2021 Nov 04;9(11): [PMID: 34822683]
  36. Eur J Epidemiol. 2009;24(7):351-5 [PMID: 19452127]
  37. Anesthesiology. 2011 Dec;115(6):1363-81 [PMID: 22020140]
  38. Drug Metab Pharmacokinet. 2012;27(4):414-21 [PMID: 22277678]
  39. JAAD Case Rep. 2023 Apr 26;36:89-91 [PMID: 37274146]
  40. Drug Alcohol Depend. 2023 Nov 1;252:110985 [PMID: 37826988]
  41. Pharmacol Ther. 2013 Apr;138(1):103-41 [PMID: 23333322]
  42. Acad Forensic Pathol. 2017 Mar;7(1):50-59 [PMID: 31239956]
  43. Forensic Sci Int. 2005 Oct 4;153(1):81-4 [PMID: 15967611]
  44. Cureus. 2024 Jan 22;16(1):e52745 [PMID: 38384599]
  45. Lancet. 2023 Nov 25;402(10416):1949-1952 [PMID: 37634523]
  46. Acad Forensic Pathol. 2018 Sep;8(3):565-615 [PMID: 31240060]
  47. Br J Pharmacol. 2023 Apr;180(7):797-812 [PMID: 34030211]
  48. Healthcare (Basel). 2021 Jul 09;9(7): [PMID: 34356248]
  49. Leg Med (Tokyo). 2024 Nov;71:102507 [PMID: 39127024]
  50. Mol Aspects Med. 2012 Oct-Dec;33(5-6):518-34 [PMID: 22705445]
  51. Front Pharmacol. 2018 Oct 26;9:1210 [PMID: 30416445]
  52. Biomolecules. 2022 Apr 19;12(5): [PMID: 35625531]
  53. Cureus. 2022 Aug 19;14(8):e28160 [PMID: 36148197]
  54. J Urban Health. 2022 Apr;99(2):316-327 [PMID: 35181834]
  55. Neurosci Biobehav Rev. 2019 Nov;106:49-57 [PMID: 30528374]
  56. Ann Palliat Med. 2021 May;10(5):5119-5127 [PMID: 33894711]
  57. Epidemiol Rev. 2020 Jan 31;42(1):154-166 [PMID: 33511987]
  58. Pain. 2008 Sep 30;139(1):5-14 [PMID: 18403122]
  59. Neurosci Res. 2004 Nov;50(3):343-54 [PMID: 15488297]
  60. Toxics. 2022 Mar 22;10(4): [PMID: 35448413]
  61. Transl Psychiatry. 2019 Nov 11;9(1):282 [PMID: 31712552]
  62. J Illicit Econ Dev. 2022;4(2):204-222 [PMID: 37009634]
  63. Clin Interv Aging. 2008;3(2):273-8 [PMID: 18686750]
  64. Biomedicines. 2020 Apr 22;8(4): [PMID: 32331352]
  65. Aging (Albany NY). 2020 Aug 3;12(15):15314-15327 [PMID: 32756006]
  66. Forensic Sci Int. 2018 Feb;283:e13-e17 [PMID: 29254806]
  67. World J Gastroenterol. 2020 Jan 14;26(2):109-133 [PMID: 31969775]
  68. J Med Toxicol. 2014 Mar;10(1):100-6 [PMID: 24132519]
  69. Rev Invest Clin. 2023;75(3):93-104 [PMID: 37441771]
  70. Eur J Pharm Sci. 2024 Mar 1;194:106689 [PMID: 38171419]
  71. Clin Toxicol (Phila). 2023 Dec;61(12):1040-1046 [PMID: 38088581]
  72. Surg Pathol Clin. 2018 Jun;11(2):297-311 [PMID: 29751876]
  73. Soc Sci Med. 2020 Jan;244:112642 [PMID: 31731136]
  74. Br J Pharmacol. 2020 Jan;177(2):254-266 [PMID: 31499594]
  75. Addiction. 2013 Jul;108(7):1287-95 [PMID: 23297783]
  76. Ann Intern Med. 2023 Oct;176(10):1370-1376 [PMID: 37812779]
  77. Subst Use Misuse. 2019;54(6):998-1006 [PMID: 30767590]
  78. Cureus. 2023 Jul 10;15(7):e41621 [PMID: 37565101]
  79. Clin Pharmacokinet. 2013 Jan;52(1):23-36 [PMID: 23100195]
  80. J Clin Med. 2024 Mar 04;13(5): [PMID: 38592322]
  81. Pharmacol Rev. 2008 Jun;60(2):196-209 [PMID: 18560012]
  82. Basic Clin Pharmacol Toxicol. 2015 Nov;117(5):358-9 [PMID: 25892448]
  83. Pharmgenomics Pers Med. 2019 Nov 27;12:361-368 [PMID: 31819591]
  84. Leg Med (Tokyo). 2022 Sep;58:102084 [PMID: 35561504]
  85. Histopathology. 2011 Oct;59(4):579-93 [PMID: 21261690]
  86. Mol Pharmacol. 2020 Oct;98(4):508-517 [PMID: 32321735]
  87. Metabolites. 2023 Aug 21;13(8): [PMID: 37623908]
  88. Front Neurosci. 2019 May 17;13:484 [PMID: 31156369]
  89. Health Promot Chronic Dis Prev Can. 2018 Jun;38(6):224-233 [PMID: 29911818]
  90. Gen Hosp Psychiatry. 2010 Nov-Dec;32(6):648.e9-648.e10 [PMID: 21112467]
  91. J Forensic Leg Med. 2023 Jul;97:102542 [PMID: 37236142]
  92. Clin Gastroenterol Hepatol. 2017 Sep;15(9):1338-1349 [PMID: 28529168]
  93. Life Sci. 2024 Oct 1;354:122966 [PMID: 39147320]
  94. Sci Rep. 2019 Oct 1;9(1):14122 [PMID: 31575947]
  95. Front Immunol. 2018 Sep 19;9:1985 [PMID: 30283435]
  96. Harm Reduct J. 2010 Oct 15;7:24 [PMID: 20950455]
  97. Drug Des Devel Ther. 2024 Feb 01;18:233-255 [PMID: 38362136]
  98. Front Immunol. 2019 Dec 12;10:2914 [PMID: 31921173]
  99. Drug Alcohol Depend. 2023 Dec 1;253:110993 [PMID: 37883846]
  100. Future Med Chem. 2014 Mar;6(4):385-412 [PMID: 24635521]
  101. Clin Pharmacol Ther. 2022 Apr;111(4):896-908 [PMID: 34877660]
  102. Int J Drug Policy. 2017 Aug;46:146-155 [PMID: 28735775]
  103. Forensic Sci Int. 2018 Aug;289:207-214 [PMID: 29902699]
  104. Ann Am Thorac Soc. 2015 May;12(5):765-74 [PMID: 25742123]
  105. Toxics. 2023 Oct 20;11(10): [PMID: 37888722]
  106. Front Pharmacol. 2023 Oct 26;14:1280289 [PMID: 37954845]
  107. Comput Math Organ Theory. 2019 Mar;25(1):48-59 [PMID: 32577089]
  108. Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):125-141 [PMID: 31976778]
  109. J Pers Med. 2023 May 30;13(6): [PMID: 37373907]
  110. J Pain. 2014 Dec;15(12):1215-26 [PMID: 25441689]
  111. Pharmacol Ther. 2022 May;233:108019 [PMID: 34637841]
  112. Curr Treat Options Oncol. 2023 Jul;24(7):867-879 [PMID: 37145383]
  113. Inj Prev. 2021 Aug;27(4):395-398 [PMID: 33536231]
  114. Clin Pharmacokinet. 2019 Dec;58(12):1567-1576 [PMID: 31168770]
  115. Life Sci. 2020 Apr 1;246:117400 [PMID: 32032645]
  116. BMC Neurosci. 2018 Mar 23;19(1):15 [PMID: 29571287]
  117. Front Cardiovasc Med. 2023 Feb 09;10:1104715 [PMID: 36844723]
  118. Public Health Rep. 2019 Jul/Aug;134(4):423-431 [PMID: 31211644]
  119. Curr Drug Saf. 2024 Mar 11;: [PMID: 38468528]
  120. Neurosci Insights. 2024 Apr 24;19:26331055241247156 [PMID: 39296815]
  121. J Neurosci Res. 2010 Mar;88(4):905-16 [PMID: 19798748]
  122. Clin Chim Acta. 2024 Jul 15;561:119826 [PMID: 38909977]
  123. Eur J Pharm Biopharm. 2013 Aug;84(3):449-55 [PMID: 23419814]
  124. Int J Drug Policy. 2019 Sep;71:183-188 [PMID: 30718120]
  125. Drug Alcohol Depend. 2017 Feb 01;171:107-116 [PMID: 28068563]
  126. J Clin Med. 2019 May 22;8(5): [PMID: 31121993]
  127. Differentiation. 2023 Jan-Feb;129:17-36 [PMID: 35490077]
  128. Br J Pharmacol. 1994 Sep;113(1):303-9 [PMID: 7812626]
  129. Clin Ther. 2008 Mar;30(3):469-81 [PMID: 18405786]
  130. Anesth Prog. 2015 Spring;62(1):31-9 [PMID: 25849473]
  131. Ann Med Surg (Lond). 2024 May 20;86(7):3816-3819 [PMID: 38989224]
  132. Ann Palliat Med. 2020 Mar;9(2):542-557 [PMID: 32036672]
  133. Curr Med Chem. 2012;19(33):5664-76 [PMID: 22856657]
  134. Anesth Pain Med. 2021 Sep 06;11(4):e119156 [PMID: 34692448]
  135. J Med Toxicol. 2013 Mar;9(1):34-41 [PMID: 22890811]
  136. J Addict Med. 2023 Sep-Oct 01;17(5):503-508 [PMID: 37788600]
  137. Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350 [PMID: 33965972]
  138. Xenobiotica. 2015 Mar;45(3):207-12 [PMID: 25314012]
  139. Anesth Prog. 2014 Spring;61(1):1-2 [PMID: 24697818]
  140. Cureus. 2022 Aug 5;14(8):e27708 [PMID: 36081981]
  141. Addiction. 2019 Sep;114(9):1524-1525 [PMID: 30883941]
  142. Diagnostics (Basel). 2023 Oct 10;13(20): [PMID: 37891990]
  143. Ann N Y Acad Sci. 2019 Sep;1451(1):130-143 [PMID: 31378974]
  144. J Clin Pharmacol. 2001 Jul;41(7):757-63 [PMID: 11452708]
  145. Hepatology. 2015 Mar;61(3):1066-79 [PMID: 25066777]
  146. Mol Pharmacol. 2019 Apr;95(4):386-397 [PMID: 30665971]
  147. J Addict Med. 2017 Jul/Aug;11(4):256-265 [PMID: 28590391]
  148. Nat Commun. 2021 Feb 12;12(1):984 [PMID: 33579956]
  149. Heliyon. 2023 Dec 01;9(12):e23083 [PMID: 38144320]
  150. Sci Rep. 2015 Mar 24;5:9434 [PMID: 25801186]
  151. Biomed Pharmacother. 2021 Oct;142:112060 [PMID: 34523422]
  152. Front Pharmacol. 2018 Dec 04;9:1436 [PMID: 30564130]
  153. Clin Toxicol (Phila). 2008 Apr;46(4):322-4 [PMID: 18363130]
  154. Open Respir Med J. 2012;6:63-74 [PMID: 22896776]
  155. Leg Med (Tokyo). 2001 Sep;3(3):134-40 [PMID: 12935518]
  156. Pharmaceuticals (Basel). 2023 Mar 02;16(3): [PMID: 36986482]
  157. Cell Mol Neurobiol. 2024 May 27;44(1):47 [PMID: 38801645]
  158. Forensic Sci Int. 2016 Jul;264:7-14 [PMID: 26978791]

MeSH Term

Humans
Fentanyl
Analgesics, Opioid
Opioid-Related Disorders
Pharmacogenetics
Forensic Toxicology

Chemicals

Fentanyl
Analgesics, Opioid

Word Cloud

Created with Highcharts 10.0.0fentanylmisuseFentanylopioideffectsabuseforensicpharmacogeneticsyntheticmetabolismchallengesincludingxylazinetoxicityindividualwidelyusedpotentanalgesicchronicpainmanagementintraoperativeanesthesiaHoweverhighpotencylowcostaccessibilityalsomadesignificantdrugcontributingglobalepidemicreviewaimsprovidein-depthanalysisfentanyl'smedicalapplicationspharmacokineticspharmacogeneticsexaminingadverseimplicationsSpecialattentiongivenpolydruginteractionsdeterminingcausedeathfentanyl-relatedfatalitiesescalateddramaticallydrivensubstitutionheroinavailabilityonlineplatformsdarkwebPolydrugusecombinedsubstanceslikealcoholbenzodiazepinescocaineexacerbatesincreasesriskfataloutcomesundergoesrapiddistributioninactivemetabolitesrenalexcretionGeneticpolymorphismssignificantlyinfluenceresponsesaffectingefficacypotentialFentanyl'ssideincluderespiratorydepressioncardiacarrhythmiasgastrointestinaldysfunctionneurocognitiveimpairmentsChronicdisruptsbrainfunctioncontributesmentalhealthdisordersposesrisksyoungerolderpopulationsalikeFentanyl-relateddeathsrequirecomprehensiveinvestigationsjudicialinspectionsautopsiestoxicologicalanalysesAdditionallyco-administrationpresentsdistinctscientificcommunityHistologicalimmunohistochemicalstudiesessentialunderstandingorgan-specificdamagetestingcanidentifysusceptibilitiesgrowingprevalencehighlightsneedrobustprotocolsadvancedresearchvariabilitystrategiesmitigateInternationalcollaborationpubliceducationharmreductionmeasurescriticaladdressingcrisiseffectivelyRiseFentanyl:MolecularAspectsForensicInvestigationstoxicology

Similar Articles

Cited By